OBGYN & Women’s Health

A recent survey study concluded that to encourage metastatic breast cancer patients to exercise, individualized, accessible programs with clear instructional materials should be created. To improve patient engagement and program evaluation, there is a need for country-specific strategies, reimbursement clarification, and interdisciplinary collaboration. Despite notable progress in the early detection and therapeutic interventions for breast...

Trastuzumab deruxtecan significantly improved overall survival compared to trastuzumab emtansine in a multi-center phase 3 trial. Human epidermal growth factor receptor 2 (HEGFR 2) is overexpressed in 15–20% of breast cancers. Currentlu, for HER2-positive metastatic breast cancer, pertuzumab and trastuzumab, plus a taxane, are first-line treatments. Second-line therapy is trastuzumab deruxtecan or trastuzumab emtansine, both...

Triple-negative breast cancer patients treated with immune checkpoint inhibitors may experience a greater antitumoral immune response, according to a recent literature review. Immunotherapy, especially immune checkpoint inhibitors (ICIs), has revolutionized solid tumor malignancy treatment. ICIs target immunosuppressive receptors such as programmed cell death ligand 1 (PD-L1), programmed cell death 1 (PD-1), and cytotoxic T-lymphocyte-associated protein...

Elacestrant improves progression-free survival in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer, especially in patients with estrogen receptor 1 gene mutations, according to the results of a recent literature review. Endocrine therapy is the backbone of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer treatment. Most cases...

Racial disparities in curative intent surgery, endocrine therapy, and treatment-related adverse effects were seen among women with breast cancer in a recent single-center study. Breast cancer (BC) is the most common malignancy occurring worldwide among women. Racial disparities in BC outcomes and access to treatment are well documented, but there’s a lack of evidence regarding...

Oral selective estrogen receptor degraders are effective in the estrogen receptor 1 mutation subgroup of estrogen receptor-positive metastatic breast cancer, according to the results of a new study. Oral selective estrogen receptor degraders (SERDs) are novel agents used to treat estrogen receptor (ER)-positive metastatic breast cancer resistant to other hormonal agents. Elacestrant and camizestrant have...

Obesity is a risk factor for cancer recurrence in resected hormone-sensitive breast cancer patients undergoing adjuvant chemotherapy with aromatase inhibitors, according to a recent study. Aromatase inhibitors (AIs) are extensively used for treating hormone-sensitive breast cancer (BC). In post-menopause, estrogen is mainly formed in the adipose tissue via aromatase-mediated androgen conversion, which might impair the...

Pembrolizumab plus chemotherapy significantly improves survival in advanced triple-negative breast cancer expressing programmed death ligand 1, with a combined positive score of 10 or more compared to chemotherapy alone, according to a phase 3 trial. Triple-negative breast cancer (TNBC) lacks the expression of estrogen and progesterone receptors and involves overexpression of human epidermal growth factor...

Neoadjuvant chemotherapy in combination with nab-paclitaxel and pembrolizumab shows promising pathological complete response rates. Pembrolizumab (pembro) is the only approved immune checkpoint inhibitor for the neoadjuvant treatment of early triple-negative breast cancer (TNBC). It was introduced in combination with carboplatinum/paclitaxel and anthracycline/cyclophosphamide chemotherapy. Nab-paclitaxel (nP), although not approved, is also effective in TNBC.  A study...